Nattopharma ASA is excited to announce its newly formed exclusive distribution agreement with Glanbia Nutritionals, whereby NattoPharma's new ingredient, MenaQ7® PURE, a first-in-class nature-identical synthetic vitamin K2 as menaquinone-7 (MK-7), will be distributed throughout the United States and Canada by Glanbia Nutritionals, a leader in innovative premixes for supplements and functional foods and beverages. MenaQ7® PURE was innovated by NattoPharma to serve the dietary supplement, and food and beverage industries that require purity of ingredients that deliver more physical economy during manufacturing.
A division of Glanbia plc, an international nutritional solutions and cheese group headquartered in Ireland, Glanbia Nutritionals manufactures and sells nutritional and functional ingredient solutions to the food, beverage, supplement and animal nutrition industries. The number-two global micronutrient blending provider with the largest sports nutrition brand family globally, Glanbia employs more than 5,000 employees worldwide with an operations presence in 29 countries, while distributing products in over 130 countries. Specific to Glanbia’s
U.S. and Canadian operations, the company has production facilities, warehouses, and distributors strategically placed throughout North America to capitalize on key regions and growth opportunities. Glanbia reports total group revenue of €3.3 billion (+10.5%), reflecting continued strong organic growth in both Global Performance Nutrition and Global Ingredients.
"MenaQ7 PURE is the newest offering to Glanbia Nutritionals' arsenal of unique, proprietary, branded, clinically substantiated, and validated ingredients," says Hogne Vik, CEO in NattoPharma. "The market for vitamin K2 as MK-7 is clearly expanding as the scientific evidence of its ability to promote bone and cardiovascular health continues to accumulate. As vitamin K2 awareness has been rapidly growing, NattoPharma has been fielding an influx of inquiries. Glanbia Nutritionals' broad and deep customer base will benefit from this vital new offering, which will further enhance NattoPharma’s U.S. presence.”
“This is a breakthrough for the work we have been consistently advancing in the United States, as we have said that we have been in contact with some large U.S. companies. Building strong partnerships is a long process, but one that is extremely gratifying when it comes to fruition,” continues Froce Marc Bohan, chairman of the board at NattoPharma. "Glanbia's expertise and network is a fantastic start to help create a healthier, more robust population."
NattoPharma's MenaQ7 PURE is produced in a European pharmaceutical manufacturing facility and is fully validated by numerous human clinical studies, as well as in vivo and in vitro research; it is recognized by the world’s leading experts in vitamin K2 at University of Maastricht (Netherlands) for purity and quality.